Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update
28 nov. 2017 06h40 HE
|
Auris Medical AG
HEALOS trial with AM-111 did not meet the primary efficacy endpoint, but showed statistically and clinically significant effect in profound acute hearing loss subpopulation Phase 3 results from...
Auris Medical News Release
21 nov. 2017 08h00 HE
|
Auris Medical AG
Auris Medical to Report Third Quarter 2017 Financial Results and Provide Business Update on Tuesday, November 28, 2017 Zug, Switzerland, November 21, 2017 - Auris Medical Holding AG (NASDAQ:...
Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC
11 oct. 2017 06h45 HE
|
Auris Medical AG
Zug, Switzerland, October 11, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Announces Transfer to Nasdaq Capital Market
28 sept. 2017 08h30 HE
|
Auris Medical AG
Zug, Switzerland, September 28, 2017 - Auris Medical Holding AG (the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Provides Board of Directors Update
26 sept. 2017 08h30 HE
|
Auris Medical AG
Zug, Switzerland, September 26, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
22 sept. 2017 08h00 HE
|
Auris Medical AG
Trial now includes more than 730 patients under previously announced amended protocol Top-line results from TACTT3 expected in first quarter 2018 Zug, Switzerland, September 22, 2017 - Auris...
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
20 sept. 2017 08h00 HE
|
Auris Medical AG
ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting
05 sept. 2017 08h00 HE
|
Auris Medical AG
ZUG, Switzerland, Sept. 5, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...
Auris Medical Announces Receipt of Nasdaq Notice
24 août 2017 16h05 HE
|
Auris Medical AG
Zug, Switzerland, August 24, 2017 - Auris Medical Holding AG ("the Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...
Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
10 août 2017 06h30 HE
|
Auris Medical AG
Phase 3 results from AM-111 HEALOS trial expected in fourth quarter 2017 Phase 3 results from Keyzilen® TACTT3 trial expected in first quarter 2018 Conference call set for 8 am EDT (2 pm CEST)...